- Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Hammerer-Lercher A et al. Chim Acta 2001;310(2):193-7.
Ir a sitio web
- Comparative measurement of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in ambulatory patients with heart failure. Masson S et al. Clin Chem Lab Med 2002;40(8):761-3.
Ir a sitio web
- The value of natriuretic peptides NT-pro-BNP and BNP for the assessment of left-ventricular volume and function. A prospective study of 150 patients. (Article in German) Pfister R et al. Dtsch Med Wochenschr 2002;127(49):2605-9.
Ir a sitio web
- Natriuretic Peptides (NPs): Automated Electrochemiluminescent Immunoassay for N-Terminal pro-BNP Compared with IRMAs for ANP and BNP in Heart Failure Patients and Healthy Individuals. Concetta Frontera et al. Clin Chem,2003;49(9).
Descargar pdf
- Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Palladini G et al. Circulation 2003;107(19):2440-5.
Descargar pdf
- Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Mueller T et al. Clin Chem 2003;49(6 Pt 1):976-9.
Ir a sitio web
- Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Yeo KT et al. Clin Chim Acta 2003;338(1-2):107-15.
Ir a sitio web
- Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. Gegenhuber Aet al. Clin Chem 2004;50(2):454-6.
Ir a sitio web
- A feeling in the waters: diagnosis of heart failure using urinary natriuretic peptides. Krum H, Liew D. Clin Sci (Lond) 2004;106(2):111-2.
Ir a sitio web
- Biochemical diagnosis of impaired left ventricular ejection fraction--comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Mueller T et al. Clin Chem Lab Med 2004;42(2):159-63.
Ir a sitio web
- Diagnosis of heart failure using urinary natriuretic peptides. Geeranavar S et al. Clin Sci (Lond) 2004;106(2):129-33.
Ir a sitio web
- Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Mueller T et al. Clin Chim Acta. 2004;341(1-2):41-8.
Ir a sitio web
- Use of NT-proBNP in routine testing and comparison to BNP. Pfister R et al. Eur J Heart Fail 2004;6(3):289-93.
Ir a sitio web
- Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Prontera C et al. Clin Chem Lab Med 2004;42(1):37-44.
Ir a sitio web
- Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Seino Y et al. Eur J Heart Fail 2004;6(3):295-300.
Ir a sitio web
- Long-term stability of endogenous BNP and NT-proBNP in frozen plasmas samples. Mueller T et al. Clin Chem Lab Med 2004;42(8):942-4.
Ir a sitio web
- The Effects of Ejection Fraction on NT-proBNP and BNP levels in Patients with Acute CHF: Analysis from the proBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. O'donoghue M et al. J Card Fail 2005;11(5 Suppl):9-14.
Ir a sitio web
| Estudios de Coste-Eficacia |
- N-terminal proBNP--the most cost effective way to identify post myocardial infarction left ventriular dysfunction? Struthers AD. Eur Heart J 2000;21(18):1490-2.
Ir a sitio web
- Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. Nielsen OW et al. J Am Coll Cardiol. 2003;41(1):113-20.
Ir a sitio web
- Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides. Senior R et al. J Heart 2003;89 Suppl 3:iii24-8.
Ir a sitio web
- Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. Mueller C et al. N Engl J Med 2004;350(7):647-54.
Ir a sitio web
- Cost-effectiveness of Screening with BNP to identify Patients with reduced Left Ventricular Ejection Fraction. Heidenreich PA et al. J Am Coll Cardiol 200;43(6):1019-26.
Ir a sitio web
- Is BNP-guided Heart Failure Management cost-effective ?. Morimoto T et al. Int J Cardiol 2004;96(2):177-81.
Ir a sitio web
- Use of BNP for the Management of Women with Dyspnea. Mueller C et al. Am J Cardiol 2004;94(12):1510-4.
Ir a sitio web
- Blending hospital economics with quality of care: A case study. Kleckner M 3rd. Health Financ Manage 2004;58(12):64-8, 70.
Ir a sitio web
|
| Valores de Referencia |
- Why is the concentration of plasma brain natriuretic peptide in elderly inpatients greater than normal? Sayama H et al. Coron Artery Dis 1999;10(7):537-40.
Ir a sitio web
- Changes in cardiac markers including B-natriuretic peptide in runners after the Boston marathon. Siegel AJ et al. Am J Cardiol 2001;88(8):920-3.
Ir a sitio web
- The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex. Clerico A et al. Clin Chem Lab Med 2002;40(4):371-7.
Ir a sitio web
- Post-race kinetics of cardiac troponin T and I and N-terminal pro-brain natriuretic peptide in marathon runners. Herrmann M et al. Clin Chem 2003;49(5):831-4.
Ir a sitio web
- Serum N-terminal pro-brain natriuretic peptide in normal Thai subjects. Leowattana W et al. J Med Assoc Thai 2003;86 Suppl 1:S46-51.
Ir a sitio web
- The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Raymond I et al. Heart 2003;89(7):745-51.
Descargar pdf
- Normal values of B type natriuretic peptide in infants, children, and adolescents. Koch A, Singer H. Heart 2003;89(8):875-8.
Descargar pdf
- Plasma N-terminal pro-B-type natriuretic peptide concentrations in a control population of infants and children. Rauh M, Koch A. Clin Chem 2003;49(9):1563-4.
Descargar pdf
- The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients. McLean AS et al. Crit Care Med 2003;31(11):2611-8.
Ir a sitio web
- Increases in plasma levels of atrial and brain natriuretic peptides after running a marathon: are their effects partly counterbalanced by adrenocortical steroids? Niessner A et al. Eur J Endocrinol 2003;149(6):555-9.
Descargar pdf
- Value of N-terminal pro brain natriuretic peptide in the elderly: data from the prospective Copenhagen Hospital Heart Failure study (CHHF). Wendelboe Nielsen O et al. Eur J Heart Fail 2004;6(3):275-9.
Ir a sitio web
- Biochemical indicators of cardiac and renal function in a healthy elderly population. Johnston N et al. Clin Biochem 2004;37(3):210-6.
Ir a sitio web
- Attenuation of biologic compensatory action of cardiac natriuretic peptide system with aging. Kawai K et al. Am J Cardiol 2004 ;93(6):719-23.
Ir a sitio web
|
| Diagnóstico: Screening |
- Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Hobbs FD et al. BMJ 2002;324(7352):1498.
Descargar pdf
- NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Bay M et al. J Heart 2003;89(2):150-4.
Descargar pdf
- Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. Alehagen U et al. Clin Chem 2003;49(8):1337-46.
Descargar pdf
- Identification of previously undiagnosed left ventricular systolic dysfunction: community screening using natriuretic peptides and electrocardiography. Ng LL et al. Eur J Heart Fail 2003;5(6):775-82.
Ir a sitio web
- Natriuretic peptide measurement as a screening test for overt and subclinical heart failure. Nakamura M, Hiramori K. Int J Cardiol 2003;92: 9 – 15.
Ir a sitio web
- The Epidemiology of “Asymptomatic” Left Ventricular Systolic Dysfunction: Implications for Screening. Thomas I et al. Ann Intern Med 2003;138:907-916.
Descargar pdf
- Plasma Cardiac Natriuretic Peptide Levels in Screening for Cardiac Disease. Gary Nicholls M et al. Am J Med 2004;116:561–563.
Ir a sitio web
|
| Diagnóstico: Rule Out |
- Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new marker of cardiac impairment. Hunt PJ et al. Clin Endocrinol (Oxf) 1997;47(3):287-96.
Ir a sitio web
- Biochemical detection of left-ventricular systolic dysfunction. McDonagh TA et al. Lancet 1998;351(9095):9-13.
Ir a sitio web
- Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Karl J et al. Scand J Clin Lab Invest Suppl 1999;230:177-81.
Ir a sitio web
- Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. Dao Q et al. J Am Coll Cardiol 2001;37(2):379-85.
Ir a sitio web
- Plasma amino-terminal pro-brain natriuretic peptide levels in subjects presenting to the Emergency Department with suspected acute coronary syndrome: possible role in selecting patients for follow up? Campbell DJ et al. Intern Med J 2001;31(4):211-9.
Ir a sitio web
- Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Cabanes L et al. Chest 2001;120(6):2047-50.
Descargar pdf
- Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. Morrison LK et al. J Am Coll Cardiol 2002;39(2):202-9.
Ir a sitio web
- Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Groenning BA et al. Am Heart J 2002;143(5):923-9.
Ir a sitio web
- Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. Maisel AS et al. N Engl J Med 2002;347(3):161-7.
Descargar pdf
- B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Maisel A. Rev Cardiovasc Med 2002;3 (Suppl 4):S10-7.
Descargar pdf
- NT-proBNP: FDA clears new automated lab test for congestive heart failure. T02-47 November 19, 2002.
Ir a sitio web
- Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Mir TS et al. Pediatrics 2002 ;110(6):e76.
Descargar pdf
- The role of B-type natriuretic peptide in the diagnosis of congestive heart failure in patients presenting to an emergency department with dyspnea. Villacorta H et al. Arq Bras Cardiol 2002;79(6):569-72, 564-8.
Descargar pdf
- Personal experience with determination of NT-proBNP in clinical practice (Article in Czech). Stejskal D et al. Vnitr Lek 2003;49(2):121-6.
Ir a sitio web
- Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases. Sirithunyanont C et al. J Med Assoc Thai 2003;86 Suppl 1:S87-95.
Ir a sitio web
- Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. Lainchbury JG et al. J Am Coll Cardiol 2003 ;42(4):728-35.
Ir a sitio web
- Clinical applications of B-type natriuretic peptide (BNP) testing. Cowie MR et al. Eur Heart J 2003;24(19):1710-8.
Ir a sitio web
- Value of N-Terminal proBNP in the Diagnosis of Left Ventricular Systolic Dysfunction in Primary Care Patients Referred for Echocardiography. Finn Gustafssona et al. Heart Drug 2003;3:141–146.
Ir a sitio web
- B-type natriuretic peptides: a diagnostic breakthrough for clinicians. McCullough PA et al. Rev Cardiovasc Med 2003 Spring;4(2):72-80.
Descargar pdf
- NT-proBNP and atrioventricular plane displacement. Relationship and diagnostic implications. Rivera M et al. Rev Esp Cardiol 2003;56(11):1043-9.
Descargar pdf
- Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. Wright SP et al. J Am Coll Cardiol 2003;42(10):1793-800.
Ir a sitio web
- Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Tang WH et al. Circulation 2003;108(24):2964-6.
Ir a sitio web
- Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. Goetze JP et al. J Heart Lung Transplant 2004;23(1):80-7.
Ir a sitio web
- N-terminal pro-brain natriuretic peptide for discriminating between cardiac and non-cardiac dyspnoea. Nielsen LS et al. Eur J Heart Fail 2004;6(1):63-70.
Ir a sitio web
- Vigorous response in plasma N-terminal pro-brain natriuretic peptide (NT-BNP) to acute myocardial infarction. Gill D et al. Clin Sci (Lond) 2004;106(2):135-9.
Ir a sitio web
- N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction. Bayes-Genis A et al. Eur J Heart Fail 2004;6(3):301-8.
Ir a sitio web
- Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Groenning BA et al. Heart 2004;90(3):297-303.
Ir a sitio web
- NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. McDonagh TA et al. Eur J Heart Fail 2004;6(3):269-73.
Ir a sitio web
- Measurement of Pro-Brain Natriuretic Peptide in Pleural Fluid for the Diagnosis of Pleural Effusions Due to Heart Failure. Porcel JM et al. AM J Med 2004;116: 417-420.
Ir a sitio web
- The NT-proBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Januzzi JL Jr et al. Am J Cardiol 2005;95(8):948-54.
Ir a sitio web
- Diagnostic and Prognostic Performance of NT-ProBNP in Primary Care Patients wiyh Suspected Heart Failure. Gustafsson F et al. J Card Fail 2005;11(5 Pt 2):15-20.
Ir a sitio web
- The Value of NT-proBNP for the Evaluation of Acute CHF: A multicenter International Meta-Analysis of 1256 subjects: The ICON Study. James L. Januzzi, Jr. et al. J Am Coll Cardiol 2005; 45( Suppl. A):140A.
Descargar ppt
- NTproBNP circulante, un nuevo biomarcador para el diagnóstico del paciente con disnea aguda. Bayés-Genís A. Rev Esp Cardiol 2005; 58: 1142 – 1144.
Descargar pdf
- Utilidad del NTproBNP en el manejo urgente del paciente con disnea severa y diagnóstico dudoso de insuficiencia cardíaca. Pascual Figal DA, et al. Rev Esp Cardiol 2005; 58: 1155 – 1161.
Descargar pdf
|
| Estratificación del Riesgo |
- Risk stratification using a combination of cardiac troponin T and brain natriuretic peptide in patients hospitalized for worsening chronic heart failure. Ishii J et al. Am J Cardiol 2002;89(6):691-5.
Ir a sitio web
- Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Sabatine MS et al. Circulation 2002;105(15):1760-3.
Ir a sitio web
- NT-proBNP on admisión for Early Risk Strtatification of Patients with chest pain and No ST-Segment Elevation. Jernberg T et al. J Am Coll Cardiol 2002;40(3):437-45.
Ir a sitio web
- Cardiac biomarkers for risk stratification of patients with acute pulmonary embolism. Kucher N, Goldhaber SZ. Circulation 2003;108(18):2191-4.
Descargar pdf
- Use of brain natriuretic peptide levels for risk assessment in non-ST-elevation acute coronary syndromes. White HD, French JK. J Am Coll Cardiol 2003;42(11):1917-20.
Ir a sitio web
- Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Galvani M, Ferrini D, Ottani F. Eur J Heart Fail 2004;6(3):327-33.
Ir a sitio web
- NT-proBNP Levels for Dynamic Risk Stratification of patients with acute Coronary Síndromes. Heeschen C et al. Circulation 2004;110(20):3206-12.
Ir a sitio web
- Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Schnabel R et al. Eur Heart J 2005; 26, 241–249.
Descargar pdf
- Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Gaede P et al. Diabetologia 2005;48:156-163.
Ir a sitio web
- Cardiovascular Risk Stratification in older Patients. Schillinger M. JAMA 200;293(13):1667-9.
Ir a sitio web
|
| Monitorización |
- Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Troughton RW et al. Lancet 2000;355(9210):1126-30.
Ir a sitio web
- Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Talwar S et al. Eur Heart J 2000;21(18):1514-21.
Ir a sitio web
- A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. Cheng V et al. J Am Coll Cardiol 2001;37(2):386-91.
Ir a sitio web
- The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Mair J et al. Clin Chem Lab Med 2001;39(7):571-88.
Ir a sitio web
- Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Remme WJ. Eur J Heart Fail 2002;4(1):11-22.
Ir a sitio web
- B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Yoshimura M et al. Am J Med 2002;112(9):716-20.
Ir a sitio web
- Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Latini R et al. Circulation 2002;106(19):2454-8.
Ir a sitio web
- Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Sinha AM et al. Am J Cardiol. 2003;91(6):755-8.
Ir a sitio web
- Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Fung JW et al. Am J Cardiol 2003;92(4):406-10.
Ir a sitio web
- Plasma concentrations of aminoterminal pro atrial natriuretic peptide and aminoterminal pro brain natriuretic peptide in healthy neonates: marked and rapid increase after birth. Mir TS et al. Pediatrics 2003;112(4):896-9.
Descargar pdf
- Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Packer M. Circulation 2003;108(24):2950-3.
Ir a sitio web
- Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Sliwa K et al. Circulation 2004;109(6):750-5.
Ir a sitio web
- NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Hartmann F et al. Eur J Heart Fail 2004;6(3):343-50.
Ir a sitio web
- NT-proBNP in heart failure: therapy decisions and monitoring. Richards M, Troughton RW. Eur J Heart Fail 2004;6(3):351-4.
Ir a sitio web
- Combined inhibition of angiotensin II and endothelin suppresses the brain natriuretic peptide response to developing heart failure. Rademaker MT et al. Clin Sci (Lond) 2004;106(6):569-76.
Ir a sitio web
- Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Molhoek SG et al. Heart 2004;90(1):97-8.
Ir a sitio web
- Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Kyrzopoulos S. Int J Cardiol 2005;99(3):409-13.
Ir a sitio web
- Improvement of serum NT-proBNP predicts improvement in cardiac function and favourable prognosis after cardiac resynchronization therapy for heart failure. Yu CM. J Card Fail 2005;11(5 Suppl):S42-6.
Ir a sitio web
|
| Pronóstico en IC y Cardiopatía Isquémica |
- Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Arakawa N, Nakamura M, Aoki H, Hiramori K. Cardiology 1994;85(5):334-40.
Ir a sitio web
- Plasma N-Terminal Pro–Brain Natriuretic Peptide and Adrenomedullin. New Neurohormonal Predictors of Left Ventricular Function and Prognosis After Myocardial Infarction. Richards AM et al. Circulation 1998;97:1921-1929.
Ir a sitio web
- Epidemiology, aetiology, and prognosis of heart failure. McMurray JJ, Stewart S. Heart 2000;83(5):596-602.
Descargar pdf
- Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Richards AM et al. J Am Coll Cardiol 2001;37(7):1781-7.
Ir a sitio web
- The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. de Lemos JA et al. N Engl J Med 2001;345(14):1014-21.
Ir a sitio web
- Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Crilley JG, Farrer M. Heart 2001;86(6):638-42.
Descargar pdf
- B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Harrison A et al. Ann Emerg Med 2002;39(2):131-8.
Ir a sitio web
- Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. Zugck C et al. J Am Coll Cardiol 2002;39(10):1615-22.
Ir a sitio web
- Early recanalization and plasma brain natriuretic peptide as an indicator of left ventricular function after acute myocardial infarction. Inoue T et al. Am Heart J 2002;143(5):790-6.
Ir a sitio web
- N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. Jernberg T et al. J Am Coll Cardiol 2002;40(3):437-45.
Ir a sitio web
- Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? de Lemos JA, Morrow DA. Circulation 2002;106(23):2868-70.
Ir a sitio web
- N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes. Omland T et al. Circulation 2002;106:2913-2918.
Descargar pdf
- Left ventricular remodeling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Nilsson JC et al. Am Heart J 2002;143:696- 702.
Ir a sitio web
- B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure. Berger R et al. Circulation 2002;105:2392-2397.
Descargar pdf
- N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. James SK et al. Circulation 2003;108(3):275-81.
Ir a sitio web
- N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Fisher C et al. Heart 2003;89(8):879-81.
Descargar pdf
- Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. O'Brien RJ et al. Eur J Heart Fail 2003;5(4):499-506.
Ir a sitio web
- Prognostic power of neurohumoral parameters in chronic heart failure depends on clinical stage and observation period. Berger R et al. J Heart Lung Transplant 2003;22(9):1037-45.
Ir a sitio web
- N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. Jernberg T et al. J Am Coll Cardiol 2003;42(11):1909-16.
Ir a sitio web
- Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Ishii J et al. Clin Chem 2003;49(12):2020-6.
Ir a sitio web
- B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction. Richards AM et al. Circulation 2003;107:2786-2792.
Descargar pdf
- Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clerico A, Emdin M. Clin Chem 2004;50(1):33-50.
Ir a sitio web
- NT-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials. Jernberg T et al. Eur J Heart Fail 2004;6(3):319-25.
Ir a sitio web
- N-terminal pro-brain natriuretic peptide levels in patients with non-ST-elevation myocardial infarction. Zeller M et al. Cardiology 2004;102(1):37-40.
Ir a sitio web
- N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Kirk V et al. Eur J Heart Fail 2004;6(3):335-41.
Ir a sitio web
- Plasma NT-proBNP for prediction of death or non fatal myocardial Infarction following Percutaneous Coronary Intervention. de Winter RJ et al. Am J Cardiol 2004 ;94(12):1481-5.
Ir a sitio web
- N-Terminal-Pro-Brain Natriuretic Peptide Predicts Outcome After Hospital Discharge in Heart Failure Patients. Bettencourt P et al. Circulation 2004; 110:2168-2174.
Ir a sitio web
- N-Terminal Pro-Brain Natriuretic Peptide on Admission Has Prognostic Value Across the Whole Spectrum of Acute Coronary Syndromes. Galvani M et al. Circulation 2004;110:128-134.
Ir a sitio web
- Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Bazzinoa O et al. European Heart Journal 2004; 25, 859–866.
Descargar pdf
- NT-proBNP and Long-Term Mortality in Stable Coronary Heart Disease. Kragelund C et al. Engl J Med 2005;352(7):666-75.
Ir a sitio web
- NT-proBNP , but not Anemia. Is a Powerful Predictor of Mortality in Advanced Heart Failure. Gardner RS et al. J Card Fail 2005;11(5 Suppl):47-53.
Ir a sitio web
- NT-proBNP Reduction Percentage During Admisión for Acutely Descompensated Heart Failure Predicts Long-Term Cardiovascular Mortality. Bayes-Genis A et al. J Card Fail 2005;11(5 Suppl):3-8.
Ir a sitio web
- N-Terminal pro-Brain Natriuretic Peptide, C-Reactive Protein, and Urinary Albumin Levels as Predictor of Mortality and Cardiovascular Events in Older Adults. Kistorp C et al. JAMA 2005;293(13):1609-16.
Ir a sitio web
- Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Tarnow L et al. Diabetologia 2005;48(1):149-55.
Ir a sitio web
|
| Transplantes |
- Aminoterminal pro-brain natriuretic peptide and ventricular filling pressures in heart transplant recipients. Ambrosi P et al. J Heart Lung Transplant 2003;22(7):822-5.
Ir a sitio web
- N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Gardner RS et al. Eur Heart J 2003;24(19):1735-43.
Ir a sitio web
- Usefulness of NT-proBNP Levels in predicting Survival in Heart Transplant Recipients. Ambrosi P et al. Am J Cardiol 2004;94(12):1585-7.
Ir a sitio web
- NT-proBNP is a more powefull predictor of moratlity than endothelin-1, adrenomedullin and tumour necrosis factor α in patients referred for consideration of cardiac transplantation. Gardner RS et al. Eur J Heart Fail 2005;7(2):253-60.
Ir a sitio web
|
| Función Renal |
- Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Haug C et al. Horm Metab Res 1994;26(5):246-9.
Ir a sitio web
- Increased brain natriuretic peptide and atrial natriuretic peptide plasma concentrations in dialysis-dependent chronic renal failure and in patients with elevated left ventricular filling pressure. Haug C et al. Clin Investig 1994;72(6):430-4.
Ir a sitio web
- Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Cataliotti A et al. Mayo Clin Proc 2001;76(11):1111-9
Ir a sitio web
- N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Luchner A et al. Hypertension 2002.
Ir a sitio web
- B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. McCullough PA et al. Am J Kidney Dis 2003;41(3):571-9.
Ir a sitio web
- Circulating N-terminal pro-brain natriuretic peptide and cardiac troponin T in chronic dialysis patients. Leowattana W et al. J Med Assoc Thai 2003;86 Suppl 1:S52-8.
Ir a sitio web
- B-type natriuretic peptide and renal disease. McCullough PA, Sandberg KR. Heart Fail Rev 2003;8(4):355-8.
Ir a sitio web
- Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Sarnak MJ et al. Circulation 2003;108(17):2154-69.
Ir a sitio web
- The influence of renal function on NT-proBNP levels in various disease groups. Herrmann Z et al. Clin Lab 2003;49(11-12):649-56.
Ir a sitio web
- Elimination of the Cardiac Natriuretic Peptides B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP by Hemodialysis. Wahl HG et al. Clin Chem 2004;50(6):1071-4.
Ir a sitio web
- Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. McCullough PA et al. Rev Cardiovasc Med 2004;5(1):16-25.
Descargar pdf
- N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. DeFilippi CR et al. Am J Kidney Dis 2005;46(1):35-44.
Ir a sitio web
- Diagnostic accuracy of B type natriuretic péptido and amino terminal proBNP in the emergency diagnosis of heart failure. Mueller T et al. Heart 2005;91:606-612.
Ir a sitio web
- Effect of Compensated Renal Dysfunction on Appoved Heart Failure Markers: Direct Comparison of Brain Natriuretic Peptide (BNP) and NT-proBNP. Luchner A. Hypertension. 2005;46:118.
Ir a sitio web
|
| Comunicaciones a Congresos |
- Elecsys® proBNP a new routine immunoassay to support diagnosis of chronic heart failure. Hallermayer, K., Gallusser, A., Seidel, Ch., Schenk, J., Karl, J., Rippegather, G. Roche Diagnostics GmbH, Germany. Descargar
- New Frontiers in Cardiovascular Management Clinical Experiences and State-of-the-art Research on N-terminal Pro-brain Natriuretic Peptide (NT-proBNP). KB Swedberg, C Hall, OW Nielsen, AHB Wu, FS Apple, PO Collinson, TA McDonagh, AM Richards, T Jernberg, N Kucher, CW Hamm, et al. Descargar1/2 Descargar2/2
|
| Guías de Práctica Clínica |
- Resucitación cardiopulmonar. Rev esp cardiol 1999; 52: 589-603. Descargar pdf
- Cardiología pediátrica: requerimientos de las técnicas invasivas. Rev esp cardiol 1999; 52: 688-707. Descargar pdf
- Tratamiento antitrombótico. Rev esp cardiol 1999; 52: 801-820. Descargar pdf
- Trasplante. Rev esp cardiol 1999; 52: 821-839. Descargar pdf
- Infarto agudo de miocardio. Rev esp cardiol 1999; 52: 919-956. Descargar pdf
- Cardiología nuclear. Rev esp cardiol 1999; 52: 957-989. Descargar pdf
- Desfibrilador automático implantable. Rev esp cardiol 1999; 52: 1.083-1.104. Descargar pdf
- Hipertensión arterial. Rev esp cardiol 2000; 53: 66-90. Descargar pdf
- Monitorización ambulatoria. Rev esp cardiol 2000; 53: 91-109. Descargar pdf
- Cardiología intervencionista. Rev esp cardiol 2000; 53: 218–240. Descargar pdf
- Cirugía coronaria. Rev esp cardiol 2000; 53: 241–266. Descargar pdf
- Miocardiopatías. Rev esp cardiol 2000; 53: 360–393. Descargar pdf
- Pericardio. Rev esp cardiol 2000; 53: 394–412. Descargar pdf
- Aorta. Rev esp cardiol 2000; 53: 531–541. Descargar pdf
- Resonancia magnética. Rev esp cardiol 2000; 53: 542–559. Descargar pdf
- Ecocardiografía. Rev esp cardiol 2000; 53: 663–683. Descargar pdf
- Actividad física. Rev esp cardiol 2000; 53: 684–726. Descargar pdf
- Angina inestable. Rev esp cardiol 2000; 53: 838–850. Descargar pdf
- Marcapasos. Rev esp cardiol 2000; 53: 947–966. Descargar pdf
- Angina estable. Rev esp cardiol 2000; 53: 967–996. Descargar pdf
- Pruebas de esfuerzo. Rev esp cardiol 2000; 53: 1063–1094. Descargar pdf
- Prevención y rehabilitación. Rev esp cardiol 2000; 53: 1095–1120. Descargar pdf
- Valvulopatías. Rev esp cardiol 2000; 53: 1209–1278. Descargar pdf
- Endocarditis. Rev esp cardiol 2000; 53: 1384–1396. Descargar pdf
- Cardiopatía en el embarazo. Rev esp cardiol 2000; 53: 1474–1495. Descargar pdf
- Cardiopatía congénita: postoperatorio. Rev esp cardiol 2000; 53: 1496–1526. Descargar pdf
- Cardiopatías congénitas en el recién nacido. Rev esp cardiol 2001; 54: 49–66. Descargar pdf
- Cardiopatía congénitas mas frecuentes. Rev esp cardiol 2001; 54: 67–82. Descargar pdf
- Cirugía no cardiaca. Rev esp cardiol 2001: 54: 186-193. Descargar pdf
- Hipertensión pulmonar. Rev esp cardiol 2001: 54: 194-210. Descargar pdf
- Arritmias cardiacas. Rev esp cardiol 2001; 54:307-367. Descargar pdf
- Unidad coronaria: requerimientos. Rev esp cardiol 2001; 54: 617-623. Descargar pdf
- Cardiología intervencionista y hemodinámica: requerimientos. Rev esp cardiol 2001; 54: 741-750. Descargar pdf
- Electrofisiología: requerimientos. Rev esp cardiol 2001; 54:887-891. Descargar pdf
- Actualización 2002. Rev esp cardiol 200. Descargar pdf
- Actualización 2003. Rev esp cardiol 2003; 56(5):487-97. Descargar pdf
- Adaptación española de la guía europea de prevención cardiovascular. Descargar pdf
- AHA guidelines. Ir a sitio web
- ESC Guidelines. Ir a sitio web
- Guía europea de prevención cardiovascular en la práctica clínica. Tercer grupo de trabajo de las sociedades europeas y otras sociedades sobre prevención cardiovascular en la práctica clínica (constituido por representantes de ocho sociedades y expertos invitados). Descargar pdf
- Guías de práctica clínica de la sociedad española de cardiología en insuficiencia cardiaca y shock cardiogénico. Ir a sitio web
- National Guideline Clearinghouse. Ir a sitio web
- Guidelines for the diagnosis and treatment of chronic heart failure: full test (update 2005). European Society of Cardiology. Descargar pdf
- Guidelines on the diagnosis and treatment of acute heart failure-full test. European Society of Cardiology. Descargar pdf
- Guías de práctica clínica sobre el diagnóstico y tratamiento de la insuficiencia cardiaca crónica. Versión resumida, actualización 2005. Descargar pdf
| Varios |
|
Cardiotoxicidad
- Elevated B-type natriuretic peptide levels after anthracycline administration. Suzuki T et al. Am Heart J 1998;136(2):362-3.
Ir a sitio web
- Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma. Nousiainen T et al. Eur J Haematol 1999;62(2):135-41.
Ir a sitio web
- Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Snowden JA et al. Bone Marrow Transplant 2000;26(3):309-13.
Ir a sitio web
- Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Okumura H et al. Acta Haematol 2000;104(4):158-63.
Ir a sitio web
- Prospective evaluation of anthracycline-related early cardiac damage: how do we monitor it? Ciotti R et al. J Clin Oncol 2001;19(22):4269-70.
Descargar pdf
- Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. Nousiainen T et al. J Intern Med 2002;251(3):228-34.
Ir a sitio web
- Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Gharib MI, Burnett AK. Eur J Heart Fail 2002;4(3):235-42.
Ir a sitio web
- Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children. Poutanen T et al. J Clin Oncol 2003;21(12):2349-56.
Descargar pdf
- Chemotherapy-related cardiotoxicity: new diagnostic and preventive strategies. Benvenuto GM et al. Ital Heart J 2003;4(10):655-67.
Ir a sitio web
Obesidad
Impact of obesity on plasma natriuretic peptide levels. Wang TJ et al. Circulation 2004;109(5):594-600.
Ir a sitio web
Effect of gastric banding on aminoterminal pro-brain natriuretic peptide in the morbidly obese. Hanusch-Enserer U et al. Obes Res 2003;11(6):695-8.
Ir a sitio web
Increased lipolysis in adipose tissue and lipid mobilization to natriuretic peptides during low-calorie diet in obese women. Sengenes C et al. Int J Obes Relat Metab Disord 2002;26(1):24-32.
Ir a sitio web
Obesity and the risk of heart failure. Kenchaiah S et al. N Engl J Med 2002;347(5):305-13.
Ir a sitio web
Effect of body mass index on natriuretic peptide levels in patients with acute cngestive Heart failure.-A proBNP Investigation of dyspnea in the Emergency Department (PRIDE) substudy. Krauser DG et al. Am Heart J 2005;149(4):744-50.
Ir a sitio web
Obesity and suppressed B-Type natriuretic peptide levels in Heart Failure. Mehra MR et al. J Am Coll Cardiol 2004;43(9):1590-5.
Ir a sitio web
N-Terminal pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure. Hermann-Arnhof KM et al. Clin Chem 2005;51(1):138-43.
Ir a sitio web
Estenósis aórtica
- Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Bergler-Klein J et al. Circulation 2004;109(19):2302-8.
Ir a sitio web
- Relation of N-terminal proB-Type Natriuretic Peptide to Severity of Valvular Aortic Stenosis.Am J Cardiology 2004. Weber M et al. Am J Cardiol 2004;94(6):740-5.
Ir a sitio web
- Natriuretic peptides in patients with aortic stenosis. Wei Qi et al. Am Heart J 2001;142(4): 725-732.
Ir a sitio web
- Plasma N-terminal pro BNP and cardiotrophin-1 are elevated in aortic stenosis. Talwar S et al. Eur J Heart Fail 2001;3(1):15-9.
Ir a sitio web
- Relation of NT-proBNP to progression of aortic valve disease. Weber M et al. Eur Heart J 2005;26:1023-1030.
Hipertensión
Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Talwar S et al. Heart 2000;83(3):278-82.
Descargar pdf
Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. Mukerjee D et al. Respir Med 2003;97(11):1230-6.
Ir a sitio web
Plasma Brain Natriuretic peptide Levels Increase in Proportion to the Extent of Right Ventricular Dysfuction in Pulmonary Hypertension. Nagaya N et al. J Am Coll Cardiol 1998;31(1):202-8.
Ir a sitio web
Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Nagaya N et al. J Cardiol 2001;37(2):110-1.
Ir a sitio web
Hipertensión y valores de NT-proBNP. Su importancia en el diagnóstico de insuficiencia cardíaca. Rivera M et al. Rev Esp Cardiol 2004;57:396-402.
Descargar pdf
N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers. Allanore Y et al. Arthritis Rheum 2003;48(12):3503-8.
Ir a sitio web
N-terminal pro brain natriuretic peptide in arterial hypertension - a marker for left ventricular dimensions and prognosis. Hildebrandt P et al. Eur J Heart Fail 2004;6(3):313-7.
Ir a sitio web
Tromboembolismo pulmonar
- NT-proBNP in patients with acute pulmonary embolism. Pruszczyk P et al. Eur Respir J 2003;22(4):649-53.
Descargar pdf
Insuficiencia cardíaca severa
Utility of B-type natriuretic peptide for the evaluation of intensive care unit Shock.-Crit Care Med 2004. Tung RH et al. Crit Care Med 2004;32(8):1643-7.
Ir a sitio web
Value of B-Type Natriuretic Peptide for Identifying Significantly Elevated Pulmonary Artery Wedge Pressure in Patients Treated for Established Chronic Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. Parsonage WA et al. Am J Cardiol 2005;95(7):883-5.
Ir a sitio web
B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. O'Neill JO et al. Am Heart J 2005;149(2):363-9.
Ir a sitio web
Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. Drazner MH, de Lemos JA. Am Heart J 2005;149(2):187-9.
Ir a sitio web
NT-ProBNP in Acute Heart Failure: Correlation With Invasively Measured Hemodynamic Parameters During Recompensation. Knebel F et al .J. Card Fail 2005;11(5 Suppl):38-41.
Ir a sitio web
Otros
Atrial natriuretic peptide deposited as atrial amyloid fibrils. Johansson B et al. Biochem Biophys Res Commun 1987;148(3):1087-92.
Ir a sitio web
The relation of atrial natriuretic factor to isolated atrial amyloid. Johansson B, Westermark P. Exp Mol Pathol 1990;52(3):266-78.
Ir a sitio web
Atrial amyloid deposits in the failing human heart display both atrial and brain natriuretic peptide-like immunoreactivity. Pucci A et al. J Pathol 1991;165(3):235-41.
Ir a sitio web
Stimulation of brain natriuretic peptide release from the heart by thyroid hormone. Kohno M et al. Metabolism 1993;42(8):1059-64.
Ir a sitio web
Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Morita E et al. Circulation 1993;88(1):82-91.
Ir a sitio web
Skeletal overgrowth in transgenic mice that overexpress brain natriuretic peptide. Suda M et al. Proc Natl Acad Sci U S A 1998;95(5):2337-42.
Descargar pdf
Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. Takemura G et al. J Am Coll Cardiol 1998;31(4):754-65.
Ir a sitio web
Smoking, blood pressure and serum albumin are major determinants of carotid atherosclerosis in dialysis patients. CREED Investigators. Cardiovascular Risk Extended Evaluation in Dialysis patients. Malatino LS et al. J Nephrol 1999;12(4):256-60.
Ir a sitio web
Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Downie PF et al. Clin Sci 1999;97: 255–258.
Descargar pdf
Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Hillege HL et al. Circulation 2000;102(2):203-10.
Ir a sitio web
Towards a blood test for heart failure: the potential use of circulating natriuretic peptides. Talwar S et al. Br J Clin Pharmacol 2000;50(1):15-20.
Descargar pdf
Circulating interleukin-6 significantly correlates to thyroid hormone in acute myocardial infarction but not in chronic heart failure. Nishino M et al. J Endocrinol Invest 2000;23(8):509-14.
Ir a sitio web
Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Schulz H et al. Scand J Clin Lab Invest 2001; 61: 33 - 42.
Ir a sitio web
Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. Clerico A et al. J Endocrinol Invest 2001;24(1):24-30. Jan;39(1):99-104.
Ir a sitio web
Differential expression and synthesis of natriuretic peptides determines natriuretic peptide receptor expression in primary cultures of human proximal tubular cells. Mistry SK et al. J Hypertens 2001;19(2):255-62.
Ir a sitio web
Time course of gene expression in rat experimental autoimmune myocarditis. Hanawa H et al. Clin Sci (Lond) 2002;103(6):623-32.
Descargar pdf
La «epidemia» de insuficiencia cardíaca: ¿son todos los que están y están todos los que son? Alonso-Pulpón L. Rev Esp Cardiol 2002;55(3):211-4.
Descargar pdf
Mortalidad por insuficiencia cardíaca en España, 1977-1998. Boix R et al. Rev Esp Cardiol 2002;55(3):219-26.
Descargar pdf
Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for Left Ventricular Systolic Dysfunction in the general population. Nielsen OW et al. J Am Coll Cardiol 2003;41(1):113-20.
Ir a sitio web
Triiodothyronine increases brain natriuretic peptide (BNP) gene transcription and amplifies endothelin-dependent BNP gene transcription and hypertrophy in neonatal rat ventricular myocytes. Liang F et al. J Biol Chem 2003;278(17):15073-83.
Descargar pdf
NT-proBNP: UTILIDAD CLÍNICA EN LA PATOLOGÍA CARDIACA Tapia E et al. Boletín Informativo Servicio Bioquímica Clínica del Hospital Universitario Central de Asturias 2003;1(2).
Descargar pdf
N-Terminal ProBNP: Marker of Systolic Dysfunction or Nonspecific Indicator of Cardiac Disease? Omland T. Heart Drug 2003;3:122–124.
Descargar pdf
Renal function and risk stratification in acute coronary syndromes. Wison S et al. Am J Cardiol 2003;91(9):1051-4.
Ir a sitio web
Plasma N-terminal pro-brain natriuretic peptide in Type 1 diabetic patients with and without diabetic nephropathy. Siebenhofer A et al. Diabet Med 2003;20(7):535-9.
Ir a sitio web
B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart: importance of cyclic GMP. Rosenkranz AC et al. Diabetes 2003;52(9):2389-95.
Descargar pdf
Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Henriksen JH et al. Gut 2003;52(10):1511-7.
Descargar pdf
Brain natriuretic peptide is elevated in outpatients with atrial fibrillation. Silvet H et al. Am J Cardiol 2003;92(9):1124-7.
Ir a sitio web
Acute Decompensated Heart Failure: A Contemporary Approach to Pharmacotherapeutic Management. McBride BF, White CM. Pharmacotherapy 2003:23(8):997-1020.
Ir a sitio web
Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. Mueller C et al. N Engl J Med 2004;350(7):647-54.
Ir a sitio web
Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Cataliotti A et al. Circulation 2004;109(13):1680-5.
Ir a sitio web
Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Hamad AM et al. Am J Physiol Lung Cell Mol Physiol 2003;285(5):L973-83.
Ir a sitio web
Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. Sutton TM et al. J Am Coll Cardiol 2003;41(12):2280-7.
Ir a sitio web
Prognostication of Survival using Cardiac Troponins and N-terminal pro-Brain Natriuretic Peptide in Patients with Primary Systemic Amyloidosis Undergoing Peripheral Blood Stem Cell Transplant. Dispenzieri A et al. Blood 2004.
Descargar pdf
|
|
|
